References
1. Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis.
Blood. 2020;135(16):1332-1343.
2. Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin
levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr
Blood Cancer. 2008;50(6):1227-1235.
3. Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic
lymphohistiocytosis. Blood. 2011;118(15):4041-4052.
4. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and
therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr
Blood Cancer. 2007;48(2):124-131.
5. Ravelli A, Minoia F, Davi S, et al. 2016 Classification Criteria for
Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic
Arthritis: A European League Against Rheumatism/American College of
Rheumatology/Paediatric Rheumatology International Trials Organisation
Collaborative Initiative. Arthritis Rheumatol. 2016;68(3):566-576.
6. Parodi A, Davi S, Pringe AB, et al. Macrophage activation syndrome in
juvenile systemic lupus erythematosus: a multinational multicenter study
of thirty-eight patients. Arthritis Rheum. 2009;60(11):3388-3399.
7. Rungrojjananon N, Pakakasama S, Winaichatsak A, et al. Pediatric
hemophagocytic lymphohistiocytosis in a tropical country: Results of a
multicenter study in Thailand. Asia Pac J Clin Oncol.
2023;19(2):e128-e137.
8. Bin Q, Gao JH, Luo JM. Prognostic factors of early outcome in
pediatric hemophagocytic lymphohistiocytosis: an analysis of 116 cases.
Ann Hematol. 2016;95(9):1411-1418.
9. Xu XJ, Wang HS, Ju XL, et al. Clinical presentation and outcome of
pediatric patients with hemophagocytic lymphohistiocytosis in China: A
retrospective multicenter study. Pediatr Blood Cancer.
2017;64(4):e26264.
10. Yanagaisawa R, Matsuda K, Ohga S, et al. Factors predicting the
recurrence of Epstein-Barr virus-associated hemophagocytic
lymphohistiocytosis in children after treatment using the HLH-2004
protocol. Int J Hematol. 2019;109(5):612-617.
11. Debaugnies F, Mahadeb B, Ferster A, et al. Performances of the
H-Score for Diagnosis of Hemophagocytic Lymphohistiocytosis in Adult and
Pediatric Patients. Am J Clin Pathol. 2016;145(6):862-870.
12. Matics TJ, Sanchez-Pinto LN. Adaptation and Validation of a
Pediatric Sequential Organ Failure Assessment Score and Evaluation of
the Sepsis-3 Definitions in Critically Ill Children. JAMA Pediatr.
2017;171(10):e172352.
13. Padungmaneesub W, Reungrongrat S, Manowong S, et al. Biomarkers of
disseminated intravascular coagulation in pediatric intensive care unit
in Thailand. Int J Lab Hematol. 2019;41(1):32-38.
14. Chanthong S, Choed-Amphai C, Manowong S, et al. Rotational
Thromboelastometry and Clot Waveform Analysis as Point-of-Care Tests for
Diagnosis of Disseminated Intravascular Coagulation in Critically Ill
Children in Thailand. Pediatr Crit Care Med. 2024 Feb 1. [online ahead
of print].
15. Hines MR, von Bahr Greenwood T, Beutel G, et al. Consensus-Based
Guidelines for the Recognition, Diagnosis, and Management of
Hemophagocytic Lymphohistiocytosis in Critically Ill Children and
Adults. Crit Care Med. 2022;50(5):860-872.
16. Marsh RA, Jordan MB, Talano JA, et al. Salvage therapy for
refractory hemophagocytic lymphohistiocytosis: A review of the published
experience. Pediatr Blood Cancer. 2017;64(4).
17. Kaya Z, Bay A, Albayrak M, et al. Prognostic Factors and Long-Term
Outcome in 52 Turkish Children With Hemophagocytic Lymphohistiocytosis.
Pediatr Crit Care Med. 2015;16(6):e165-173.
18. Koh KN, Im HJ, Chung NG, et al. Clinical features, genetics, and
outcome of pediatric patients with hemophagocytic lymphohistiocytosis in
Korea: report of a nationwide survey from Korea Histiocytosis Working
Party. Eur J Haematol. 2015;94(1):51-59.
19. Wang YR, Qiu YN, Bai Y, Wang XF. A retrospective analysis of 56
children with hemophagocytic lymphohistiocytosis. J Blood Med.
2016;7:227-231.
20. Beken B, Aytac S, Balta G, et al. The clinical and laboratory
evaluation of familial hemophagocytic lymphohistiocytosis and the
importance of hepatic and spinal cord involvement: a single center
experience. Haematologica. 2018;103(2):231-236.
21. Goldman J, Desai MS, McClain KL, et al. Hepatobiliary Dysfunction
and Disseminated Intravascular Coagulation Increase Risk of Mortality in
Pediatric Hemophagocytic Lymphohistiocytosis. Pediatr Crit Care Med.
2018;19(10):e522-e530.
22. Li X, Yan H, Zhang X, et al. Clinical profiles and risk factors of
7-day and 30-day mortality among 160 pediatric patients with
hemophagocytic lymphohistiocytosis. Orphanet J Rare Dis. 2020;15(1):229.
23. Cui Y, Shi J, Lu G, et al. Prognostic death factors in secondary
hemophagocytic lymphohistiocytosis children with multiple organ
dysfunction syndrome receiving continuous renal replacement therapy: A
multicenter prospective nested case-control study. Ther Apher Dial.
2022;26(5):1023-1029.
24. Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis
of hemophagocytic lymphohistiocytosis: Recommendations from the North
American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer.
2019;66(11):e27929.
FIGURE 1 Receiver Operating Characteristic (ROC) curves for
predicting R/R HLH using age and pSOFA score. (A) ROC curve for age with
a cutoff of less than 3 years, demonstrating an AUC of 0.69 and a 95%
CI of 0.59 – 0.79. (B) ROC curve for pSOFA score with a cutoff of ≥ 8,
showing an AUC of 0.76 and a 95% CI of 0.66 – 0.86.
FIGURE 2 (A) Kaplan-Meier Survival Curves showing Overall
Survival (OS) in childhood HLH, indicating a 5-year OS rate of 55.9%
(95% CI 42.0 – 67.7%). (B) Comparison of 5-year OS rates between
groups: 87.2% (95% CI 72.9 – 94.2%) in the non-R/R HLH group versus
9.0% (95% CI 1.7 – 24.0%) in the R/R HLH group (p <
0.001).